btov Partners co-leads heartbeat medical’s EUR 5m Series A together with HV Holtzbrinck Ventures.

Having known the company for over three years, we believe the window of opportunity for a solution like heartbeat could not be any more open. This can be explained by an increasing materialization of value-based health care and corresponding regulatory emphasis of:

– PROMs (patient-reported outcome measures) as a factor of health care budget allocation

– RWE (real-world evidence) as a central component in drug development

It’s an absolute pleasure to join heartbeat medical’s mission to shape the future of clinical treatments, processes and drug development through its patient feedback data platform.

Read more here.